#1 Clinical Trials Search in Europe

Esflurbiprofen

Esflurbiprofen, a novel non-steroidal anti-inflammatory drug (NSAID), is being studied in various clinical trials for its potential in treating different types of pain. This article summarizes the key findings from several studies investigating the efficacy and safety of Esflurbiprofen, particularly in its topical form as a hydrogel patch. The trials focus on conditions such as acute soft tissue injuries, knee osteoarthritis, and ankle sprains, comparing Esflurbiprofen to placebo and other established pain relief medications.

Table of Contents

What is Esflurbiprofen?

Esflurbiprofen is a medication that belongs to a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). It is specifically the S-enantiomer of flurbiprofen, which means it is a purified form of the active component of flurbiprofen[1]. Esflurbiprofen is being developed as a new treatment option for various pain and inflammatory conditions.

How Does It Work?

Esflurbiprofen works by inhibiting an enzyme called cyclooxygenase (COX)[2]. This enzyme is responsible for producing substances in the body that cause pain, fever, and inflammation. By blocking this enzyme, esflurbiprofen helps reduce these symptoms, providing relief to patients suffering from various painful conditions.

Conditions Treated

Based on the clinical trials information, esflurbiprofen is being studied for the treatment of several conditions:

  • Soft tissue injuries: This includes strains, sprains, bruises, and contusions, particularly those resulting from blunt trauma or sports injuries[2].
  • Knee osteoarthritis: A common form of arthritis that causes pain and stiffness in the knee joints[3].
  • Ankle sprains: Injuries to the ligaments in the ankle, often caused by twisting or rolling the ankle[4].

Forms and Administration

Esflurbiprofen is being developed in different forms for patient use:

  • Hydrogel patch: A patch containing 165 mg of esflurbiprofen that is applied to the skin once daily[2]. This allows the medication to be absorbed through the skin directly to the affected area.
  • Plaster: Similar to the hydrogel patch, this form contains 40 mg of esflurbiprofen and is applied to the skin[3].

These topical forms of administration may offer advantages over oral medications, as they can provide targeted relief with potentially fewer systemic side effects.

Clinical Trials

Several clinical trials are being conducted to evaluate the safety and efficacy of esflurbiprofen:

  • A study comparing esflurbiprofen hydrogel patch to a placebo for treating soft tissue injuries[2].
  • A trial comparing esflurbiprofen plaster to diclofenac gel for knee osteoarthritis pain[3].
  • A study evaluating esflurbiprofen hydrogel patch for acute pain due to ankle sprains[4].
  • A bioavailability study comparing the esflurbiprofen patch to oral flurbiprofen tablets[1].

Potential Benefits

Based on the ongoing clinical trials, esflurbiprofen may offer several potential benefits:

  • Targeted pain relief for soft tissue injuries and joint pain
  • Reduced inflammation in affected areas
  • Convenient once-daily application (for patch formulations)
  • Potentially fewer systemic side effects compared to oral NSAIDs
  • Improved mobility and function for patients with osteoarthritis or sports injuries

Safety and Side Effects

As with all medications, esflurbiprofen may cause side effects. The clinical trials are designed to assess the safety profile of this drug. Some potential areas of concern being monitored include:

  • Local skin reactions: Since the medication is applied to the skin, researchers are evaluating potential skin irritation or allergic reactions[1].
  • Patch adhesion: For the patch formulations, researchers are assessing how well the patch stays attached to the skin[1].
  • Systemic effects: While topical application may reduce systemic exposure, researchers are still monitoring for potential side effects typical of NSAIDs, such as gastrointestinal issues or cardiovascular effects.

It’s important to note that esflurbiprofen is still under investigation, and its full safety profile will be better understood as more clinical trial data becomes available. Patients should always consult with their healthcare provider about the potential risks and benefits of any medication.

Aspect Details
Drug Name Esflurbiprofen
Administration Form Hydrogel Patch (Topical)
Conditions Studied Acute soft tissue injuries, Knee osteoarthritis, Ankle sprains
Primary Outcomes Pain reduction (measured by Visual Analogue Scale)
Secondary Outcomes Global efficacy, Local tolerability, Patch adhesion, Time to pain reduction
Comparators Placebo, Diclofenac gel, Oral flurbiprofen tablets
Duration of Studies Ranging from 7 days to 2 weeks
Safety Assessments Adverse events, Local skin reactions, Bioavailability

FAQ

  • What is Esflurbiprofen and how does it work? Esflurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX), an enzyme involved in pain and inflammation. It is being studied in topical form, such as hydrogel patches, for localized pain relief.
  • What conditions are being studied using Esflurbiprofen? Clinical trials are investigating Esflurbiprofen for various conditions, including acute soft tissue injuries (like strains, sprains, and bruises), knee osteoarthritis pain, and ankle sprains.
  • How is Esflurbiprofen administered in these trials? In most trials, Esflurbiprofen is administered as a topical hydrogel patch. For example, one study used a patch containing 165 mg of Esflurbiprofen applied once daily, while another used a patch containing 40 mg of Esflurbiprofen applied for 2 weeks.
  • What are the main outcomes being measured in these trials? The trials primarily measure pain reduction using various scales, such as the Visual Analogue Scale (VAS). They also assess factors like global efficacy, local tolerability, patch adhesion, and the time taken to achieve meaningful pain reduction.
  • Are there any side effects associated with Esflurbiprofen use? While specific side effects are not detailed in the trial summaries, the studies are monitoring for adverse events and local skin reactions. One trial specifically assessed local tolerability and skin irritation as part of its secondary outcomes.

Ongoing Clinical Trials on Esflurbiprofen

  • Study on Esflurbiprofen and Paracetamol for Pain Relief in Patients with Limb Bruises

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Germany

  • Study on Esflurbiprofen Topical System and Paracetamol for Pain Relief in Patients with Acute Ankle Sprains

    Not recruiting

    1 1 1
    Investigated drugs:
    Germany

Glossary

  • Esflurbiprofen: A non-steroidal anti-inflammatory drug (NSAID) being studied for pain relief, particularly in topical form such as hydrogel patches.
  • Cyclooxygenase (COX) inhibitor: A type of medication that blocks the action of cyclooxygenase enzymes, which are involved in producing substances that cause pain and inflammation in the body.
  • Hydrogel Patch: A type of medical patch that contains a water-based gel. In these trials, it's used to deliver Esflurbiprofen through the skin for localized pain relief.
  • Visual Analogue Scale (VAS): A measurement tool used to assess pain intensity. Patients indicate their pain level on a scale, typically from 0 (no pain) to 100 (worst pain ever).
  • Osteoarthritis: A common form of arthritis characterized by the breakdown of joint cartilage, causing pain, stiffness, and reduced mobility.
  • Soft Tissue Injury: Damage to muscles, ligaments, or tendons, often caused by sudden trauma or overuse.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Placebo: A substance or treatment with no active therapeutic effect, used as a control in testing new drugs.
  • Local Tolerability: The degree to which a medication can be applied to a specific area of the body without causing irritation or adverse reactions.
  • Area Under the Curve (AUC): A measure used in pharmacology to assess the body's total exposure to a drug over time.

References

  1. https://clinicaltrials.gov/study/NCT04505787
  2. https://clinicaltrials.gov/study/NCT04908748
  3. https://clinicaltrials.gov/study/NCT03434197
  4. https://clinicaltrials.gov/study/NCT02729207